Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats

Pharmacological Research

Volumn 64, Issue 3, 2011, Pages 226-234

  Sciolino, Natale R ^a   Zhou, Wenyi ^b   Hohmann, Andrea G ^a,b  

^a University of Georgia ^*  (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

2 Arachidonoylglycerol (2 AG); Anxiety; Endocannabinoid; Environmental aversiveness; JZL184; Monoacylglycerol lipase (MGL)

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ANXIOLYTIC AGENT; DIAZEPAM; JZL 184; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ARTICLE; AVERSIVE BEHAVIOR; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; ARACHIDONIC ACIDS; BENZODIOXOLES; CATALEPSY; DIAZEPAM; ENDOCANNABINOIDS; GLYCERIDES; MALE; MONOACYLGLYCEROL LIPASES; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION;

EID: 79959977058     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.04.010     Document Type: Article

References (78)

1. F.A. Moreira, M. Grieb, and B. Lutz Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression Best Pract Res Clin Endocrinol Metab 23 2009 133 144
2. M.N. Hill, and B.B. Gorzalka The endocannabinoid system and the treatment of mood and anxiety disorders CNS Neurol Disord Drug Targets 8 2009 451 458
3. M. Navarro, E. Hernandez, R.M. Munoz, I. del Arco, M.A. Villanua, and M.R. Carrera Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat Neuroreport 8 1997 491 496 (Pubitemid 27180108)
4. C. Arevalo, R. de Miguel, and R. Hernandez-Tristan Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters Pharmacol Biochem Behav 70 2001 123 131 (Pubitemid 32786974)
5. J. Haller, B. Varga, C. Ledent, and T.F. Freund CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents Behav Pharmacol 15 2004 299 304 (Pubitemid 39062560)
6. S. Patel, and C.J. Hillard Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling J Pharmacol Exp Ther 318 2006 304 311
7. J. Haller, F. Matyas, K. Soproni, B. Varga, B. Barsy, and B. Nemeth Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission Eur J Neurosci 25 2007 2445 2456 (Pubitemid 46625912)
8. R.J. Rodgers, P.M. Evans, and A. Murphy Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice Behav Pharmacol 16 2005 405 413 (Pubitemid 41404812)
9. J. Haller, N. Bakos, M. Szirmay, C. Ledent, and T.F. Freund The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety Eur J Neurosci 16 2002 1395 1398 (Pubitemid 35340861)
10. G. Griebel, J. Stemmelin, and B. Scatton Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents Biol Psychiatry 57 2005 261 267 (Pubitemid 40187370)
11. S. Petrosino, and V. Di Marzo FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels Curr Opin Investig Drugs 11 2010 51 62
12. A. Cippitelli, N. Cannella, S. Braconi, A. Duranti, A. Tontini, and A. Bilbao Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat Psychopharmacology (Berl) 198 2008 449 460
13. D. Piomelli, G. Tarzia, A. Duranti, A. Tontini, M. Mor, and T.R. Compton Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597) CNS Drug Rev 12 2006 21 38 (Pubitemid 44133578)
14. J.Z. Long, D.K. Nomura, R.E. Vann, D.M. Walentiny, L. Booker, and X. Jin Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo Proc Natl Acad Sci USA 106 2009 20270 20275
15. M. Scherma, J. Medalie, W. Fratta, S.K. Vadivel, A. Makriyannis, and D. Piomelli The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition Neuropharmacology 54 2008 129 140
16. J.E. Schlosburg, J.L. Blankman, J.Z. Long, D.K. Nomura, B. Pan, and S.G. Kinsey Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system Nat Neurosci 13 2010 1113 1119
17. M.P. Viveros, E.M. Marco, R. Llorente, and M. Lopez-Gallardo Endocannabinoid system and synaptic plasticity: implications for emotional responses Neural Plast 2007 10.1155/2007/52908 (Pubitemid 351201245)
18. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384 1996 83 87 (Pubitemid 26374593)
19. M.K. McKinney, and B.F. Cravatt Structure and function of fatty acid amide hydrolase Annu Rev Biochem 74 2005 411 432 (Pubitemid 40995513)
20. B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, and B.R. Martin Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc Natl Acad Sci USA 98 2001 9371 9376 (Pubitemid 32743923)
21. T.P. Dinh, D. Carpenter, F.M. Leslie, T.F. Freund, I. Katona, and S.L. Sensi Brain monoglyceride lipase participating in endocannabinoid inactivation Proc Natl Acad Sci USA 99 2002 10819 10824
22. T.P. Dinh, S. Kathuria, and D. Piomelli RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol Mol Pharmacol 66 2004 1260 1264 (Pubitemid 39411065)
23. J.L. Blankman, G.M. Simon, and B.F. Cravatt A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol Chem Biol 14 2007 1347 1356 (Pubitemid 350257008)
24. F.A. Moreira, N. Kaiser, K. Monory, and B. Lutz Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors Neuropharmacology 54 2008 141 150 (Pubitemid 350299416)
25. P.S. Naidu, S.A. Varvel, K. Ahn, B.F. Cravatt, B.R. Martin, and A.H. Lichtman Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality Psychopharmacology (Berl) 192 2007 61 70 (Pubitemid 46673891)
26. S. Kathuria, S. Gaetani, D. Fegley, F. Valino, A. Duranti, and A. Tontini Modulation of anxiety through blockade of anandamide hydrolysis Nat Med 9 2003 76 81 (Pubitemid 36098263)
27. S. Rossi, V. De Chiara, A. Musella, L. Sacchetti, C. Cantarella, and M. Castelli Preservation of striatal cannabinoid CB1 receptor function correlates with the antianxiety effects of fatty acid amide hydrolase inhibition Mol Pharmacol 78 2010 260 268
28. V. Micale, L. Cristino, A. Tamburella, S. Petrosino, G.M. Leggio, and F. Drago Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels Neuropsychopharmacology 34 2009 593 606
29. J. Haller, I. Barna, B. Barsvari, K. Gyimesi Pelczer, S. Yasar, and L.V. Panlilio Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats Psychopharmacology (Berl) 204 2009 607 616
30. A.R. Hariri, A. Gorka, L.W. Hyde, M. Kimak, I. Halder, and F. Ducci Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function Biol Psychiatry 66 2009 9 16
31. M.N. Hill, G.E. Miller, E.J. Carrier, B.B. Gorzalka, and C.J. Hillard Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress Psychoneuroendocrinology 34 2009 1257 1262
32. A. Chouker, I. Kaufmann, S. Kreth, D. Hauer, M. Feuerecker, and D. Thieme Motion sickness, stress and the endocannabinoid system PLoS One 5 2010 e10752
33. C. Schroeder, S. Batkai, S. Engeli, J. Tank, A. Diedrich, and F.C. Luft Circulating endocannabinoid concentrations during orthostatic stress Clin Auton Res 19 2009 343 346
34. R.A. Mangieri, K.I. Hong, D. Piomelli, and R. Sinha An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics Psychopharmacology (Berl) 205 2009 63 72
35. S. Sutt, S. Raud, T. Areda, A. Reimets, S. Koks, and E. Vasar Cat odour-induced anxiety - a study of the involvement of the endocannabinoid system Psychopharmacology (Berl) 198 2008 509 520 (Pubitemid 351754672)
36. J. Suarez, P. Rivera, R. Llorente, S.Y. Romero-Zerbo, F.J. Bermudez-Silva, and F.R. de Fonseca Early maternal deprivation induces changes on the expression of 2-AG biosynthesis and degradation enzymes in neonatal rat hippocampus Brain Res 1349 2010 162 173
37. A.G. Hohmann, R.L. Suplita, N.M. Bolton, M.H. Neely, D. Fegley, and R. Mangieri An endocannabinoid mechanism for stress-induced analgesia Nature 435 2005 1108 1112 (Pubitemid 40910518)
38. K.C. Fone, and M.V. Porkess Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders Neurosci Biobehav Rev 32 2008 1087 1102
39. F. Cirulli, A. Berry, L.T. Bonsignore, F. Capone, I. D'Andrea, and L. Aloe Early life influences on emotional reactivity: evidence that social enrichment has greater effects than handling on anxiety-like behaviors, neuroendocrine responses to stress and central BDNF levels Neurosci Biobehav Rev 34 2010 808 820
40. N.R. Sciolino, M. Bortolato, S.A. Eisenstein, J. Fu, F. Oveisi, and A.G. Hohmann Social isolation and chronic handling alter endocannabinoid signaling and behavioral reactivity to context in adult rats Neuroscience 168 2010 371 386
41. S.A. Eisenstein, J.R. Clapper, P.V. Holmes, D. Piomelli, and A.G. Hohmann A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy Pharmacol Res 61 2010 419 429
42. J.Z. Long, W. Li, L. Booker, J.J. Burston, S.G. Kinsey, and J.E. Schlosburg Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nat Chem Biol 5 2009 37 44
43. J.Z. Long, D.K. Nomura, and B.F. Cravatt Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism Chem Biol 16 2009 744 753
44. S.G. Kinsey, S.T. O'Neal, J.Z. Long, B.F. Cravatt, and A.H. Lichtman Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay Pharmacol Biochem Behav 2010 10.1016/j.pbb.2010.12. 002
45. A.O. Mechan, P.M. Moran, M. Elliott, A.J. Young, M.H. Joseph, and R. Green A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters, and their response to diazepam Psychopharmacology (Berl) 159 2002 188 195 (Pubitemid 34146563)
46. J. Stemmelin, C. Cohen, J.P. Terranova, M. Lopez-Grancha, P. Pichat, and O. Bergis Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders Neuropsychopharmacology 33 2008 574 587
47. G. Griebel, G. Perrault, J. Simiand, C. Cohen, P. Granger, and M. Decobert SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors J Pharmacol Exp Ther 298 2001 753 768 (Pubitemid 32673429)
48. S.G. Kinsey, J.Z. Long, S.T. O'Neal, R.A. Abdullah, J.L. Poklis, and D.L. Boger Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain J Pharmacol Exp Ther 330 2009 902 910
49. J. Guindon, A. Guijarro, D. Piomelli, and A.G. Hohmann Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain Br J Pharmacol 2010 10.1111/j.1476-5381.2010.01192.x
50. J.M. Spradley, J. Guindon, and A.G. Hohmann Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms Pharmacol Res 62 2010 249 258
51. S. Pellow, P. Chopin, S.E. File, and M. Briley Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat J Neurosci Methods 14 1985 149 167 (Pubitemid 16239568)
52. R.G. Pertwee, and T.M. Ross Drugs which stimulate or facilitate central cholinergic transmission interact synergistically with delta-9- tetrahydrocannabinol to produce marked catalepsy in mice Neuropharmacology 30 1991 67 71
53. E.J. Rahn, A. Makriyannis, and A.G. Hohmann Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats Br J Pharmacol 152 2007 765 777 (Pubitemid 350041538)
54. W.J. Martin, A.G. Hohmann, and J.M. Walker Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects J Neurosci 16 1996 6601 6611 (Pubitemid 26337381)
55. J. Cohen Statistical power analysis for the behavioral sciences 2nd ed. 1998 Lawrence Erlbaum Associates New York
56. T.R. Levine, and C.R. Hullett Eta squared, partial eta squared, and misreporting of effect size in communication research Hum Commun Res 28 2002 612 625 (Pubitemid 37496224)
57. C.A. Pierce, R.A. Block, and H. Aguinis Cautionary note on reporting eta-squared values from multifactor ANOVA designs Educ Psychol Meas 64 2004 916 924 (Pubitemid 39604741)
58. J. Haller, B. Varga, C. Ledent, I. Barna, and T.F. Freund Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice Eur J Neurosci 19 2004 1906 1912 (Pubitemid 38482578)
59. M.N. Hill, R.J. McLaughlin, A.C. Morrish, V. Viau, S.B. Floresco, and C.J. Hillard Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis Neuropsychopharmacology 34 2009 2733 2745
60. S.F. Lisboa, L.B. Resstel, D.C. Aguiar, and F.S. Guimaraes Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test Eur J Pharmacol 593 2008 73 78
61. A. Roohbakhsh, S. Keshavarz, P. Hasanein, M.E. Rezvani, and A.H. Moghaddam Role of endocannabinoid system in the ventral hippocampus of rats in the modulation of anxiety-like behaviours Basic Clin Pharmacol Toxicol 105 2009 333 338
62. H.C. Lin, S.C. Mao, C.L. Su, and P.W. Gean The role of prefrontal cortex CB1 receptors in the modulation of fear memory Cereb Cortex 19 2009 165 175
63. T. Rubino, N. Realini, C. Castiglioni, C. Guidali, D. Vigano, and E. Marras Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex Cereb Cortex 18 2008 1292 1301 (Pubitemid 351769783)
64. S. Di, R. Malcher-Lopes, V.L. Marcheselli, N.G. Bazan, and J.G. Tasker Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons Endocrinology 146 2005 4292 4301 (Pubitemid 41324025)
65. T. Hayase, Y. Yamamoto, and K. Yamamoto Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands Behav Pharmacol 16 2005 395 404 (Pubitemid 41404811)
66. J.E. Schlosburg, B.L. Carlson, D. Ramesh, R.A. Abdullah, J.Z. Long, and B.F. Cravatt Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice AAPS J 11 2009 342 352
67. M.N. Hill, E.J. Carrier, W.S. Ho, L. Shi, S. Patel, and B.B. Gorzalka Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus Hippocampus 18 2008 221 226 (Pubitemid 351413487)
68. D.J. Rademacher, S.E. Meier, L. Shi, W.S. Ho, A. Jarrahian, and C.J. Hillard Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice Neuropharmacology 54 2008 108 116 (Pubitemid 350299407)
69. M.N. Hill, R.J. McLaughlin, B. Bingham, L. Shrestha, T.T. Lee, and J.M. Gray Endogenous cannabinoid signaling is essential for stress adaptation Proc Natl Acad Sci USA 107 2010 9406 9411
70. S. Patel, C.T. Roelke, D.J. Rademacher, and C.J. Hillard Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling Eur J Neurosci 21 2005 1057 1069 (Pubitemid 40461057)
71. S. Patel, C.T. Roelke, D.J. Rademacher, W.E. Cullinan, and C.J. Hillard Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis Endocrinology 145 2004 5431 5438 (Pubitemid 39564580)
72. M.N. Hill, S. Patel, E.J. Carrier, D.J. Rademacher, B.K. Ormerod, and C.J. Hillard Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress Neuropsychopharmacology 30 2005 508 515 (Pubitemid 40271153)
73. R. Llorente, A. Llorente-Berzal, S. Petrosino, E.M. Marco, C. Guaza, and C. Prada Gender-dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: a possible role for the endocannabinoid system Dev Neurobiol 68 2008 1334 1347
74. F.A. Moreira, D.C. Aguiar, A.C. Campos, S.F. Lisboa, A.L. Terzian, and L.B. Resstel Antiaversive effects of cannabinoids: is the periaqueductal gray involved? Neural Plast 2009 2009 625469
75. B. Le Foll, D.A. Gorelick, and S.R. Goldberg Psychopharmacology (Berl) The future of endocannabinoid-oriented clinical research after CB1 antagonists 205 2009 171 174
76. R. Christensen, P.K. Kristensen, E.M. Bartels, H. Bliddal, and A. Astrup Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 2007 1706 1713 (Pubitemid 350100788)
77. E.J. Topol, M.G. Bousser, K.A. Fox, M.A. Creager, J.P. Despres, and J.D. Easton Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial Lancet 376 2010 517 523
78. D. Rucker, R. Padwal, S.K. Li, C. Curioni, and D.C. Lau Long term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ 335 2007 1194 1199 (Pubitemid 350273303)